This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Billion King International Limited. Active years: 2022-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2024
Title: Colin Pak Fai Yeh: Innovator in Hemoglobin Conjugates
Introduction
Colin Pak Fai Yeh is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of biomedical innovations, particularly in the development of hemoglobin conjugates. With a total of three patents to his name, Yeh is recognized for his work that aims to improve blood replacement therapies.
Latest Patents
Colin Pak Fai Yeh's latest patents include innovative solutions that utilize thiosuccinyl-crosslinked hemoglobin conjugates. These conjugates are designed to serve as blood replacement agents and therapeutic proteins. His first patent details the methods of use and preparation of these conjugates, which are essential for developing pharmaceutical compositions. The second patent focuses on thiosuccinyl-crosslinked hemoglobin analogs, which also function as blood replacement agents and outlines their preparation and application in medical treatments.
Career Highlights
Yeh is currently associated with Billion King International Limited, where he continues to advance his research and development efforts. His work is pivotal in the quest for effective blood substitutes, which can have a profound impact on medical practices and patient care.
Collaborations
Colin Pak Fai Yeh collaborates with esteemed colleagues such as Kwok Chu Butt and Norman Fung-Man Wai. Their combined expertise enhances the innovative potential of their projects and contributes to the advancement of their field.
Conclusion
Colin Pak Fai Yeh stands out as a significant figure in the realm of biomedical inventions, particularly with his advancements in hemoglobin conjugates. His contributions are poised to make a lasting impact on blood replacement therapies and pharmaceutical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile